Phase 2 Study of Rasburicase Administered by Two Different Schedules (Fixed Dosing vs. As Needed Dosing) in Patients at High Risk or Potential Risk for Tumor Lysis Syndrome.
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2013
At a glance
- Drugs Rasburicase (Primary)
- Indications Tumour lysis syndrome
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 24 May 2012 Actual patient number (82) added as reported by ClinicalTrials.gov.
- 24 May 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.